scispace - formally typeset
Journal ArticleDOI

Pegylated poly(lactide) and poly(lactide-co-glycolide) nanoparticles: preparation, properties and possible applications in drug delivery.

Konstantinos Avgoustakis
- 30 Sep 2004 - 
- Vol. 1, Iss: 4, pp 321-333
TLDR
The ability of the PLA-Peg and PLGA-PEG nanoparticles to evade rapid phagocytocis has extended the range of sites within the body that the nanoparticles can reach, which has significant implications with regard to their application in controlled drug delivery and targeting.
Abstract
The preparation, properties and potential applications in drug delivery of biocompatible and biodegradable PLA-PEG and PLGA-PEG nanoparticles are discussed. PLA-PEG and PLGA-PEG nanoparticles have been produced by emulsification-solvent evaporation, solvent displacement and salting out methods. The nanoparticles can be stored as freeze-dried powders, but an adequate amount of a suitable lyoprotectant should be added prior lyophilisation to prevent nanoparticle aggregation and retain nanoparticle redispersibility. The nanoparticles have a core-shell structure with a PLA core and a PEG coating. Their basic colloidal properties and degradation depend on copolymer composition. The PLA-PEG and PLGA-PEG nanoparticles exhibit prolonged blood circulation following intravenous administration to animals. The composition of the nanoparticles determine their biodistribution properties, probably through its effects on the effectiveness of the PEG steric barrier and the size of the nanoparticles. The ability of the PLA-PEG and PLGA-PEG nanoparticles to evade rapid phagocytocis has extended the range of sites within the body that the nanoparticles can reach, which has significant implications with regard to their application in controlled drug delivery and targeting. The PLA-PEG and PLGA-PEG nanoparticles can be loaded with a variety of bioactive agents achieving satisfactory loading, especially in the case of hydrophobic drugs. The nanoparticles have been investigated for the treatment of infectious diseases and cancer, the intravenous and mucosal delivery of proteins, and oligonucleotide and gene delivery. The results have been encouraging and PLA-PEG and PLGA-PEG nanoparticle formulations, improving the therapeutic potential of both established and new drugs, may be expected to be available in the near future.

read more

Citations
More filters
Patent

Recombinant immunotoxins for use in the treatment of cancer

TL;DR: In this article, a method for creating a neoplasia-neutral tolerogenic environment in a subject, such as one with cancer, and administering a recombinant immunotoxin is provided.
Patent

Methods for administering synthetic nanocarriers that generate humoral and cytotoxic T lymphocyte responses

TL;DR: In this article, methods for generating humoral and cytotoxic T lymphocyte (CTL) immune responses in a subject and related compositions are presented, and a method for generating CTL immune responses is described.

Original Article: Drug Delivery Novel nanoparticles for the delivery of recombinant hepatitis B vaccine

TL;DR: Evaluation of the stability and release kinetics of nanoencapsulated HBsAg in vitro in serum revealed an initial burst effect and a subsequent slower release of the antigen, but the antigenicity was not destroyed by the encapsulation process.

Complex formation by alpha-lactalbumin and polysaccharide copolymers

Juan Du
TL;DR: Complex coacervate core micelles (C3M) are nano-assemblies of interacting polyelectrolytes and copolymers with a physical structure resembling surfactant micells, which are increasingly disfavored because of their potential irritation of biological tissues.
Related Papers (5)